Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Transformation and Electroporation – V 2.0

Posted on By


Biosimilars: SOP for Transformation and Electroporation – V 2.0


Standard Operating Procedure for Transformation and Electroporation in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/005/2025
Supersedes SOP/BS/005/2022
Page No. Page 1 of 13
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To outline the standardized procedure for introducing recombinant plasmids into host cells using chemical transformation and electroporation methods in biosimilar development workflows.

2. Scope

This SOP is applicable to laboratory personnel involved in bacterial transformation processes using competent E. coli strains within the Biosimilars R&D facility.

3. Responsibilities

  • Research Associate: Performs transformation and electroporation procedures.
  • Technician: Prepares reagents and media, and assists in plate incubation and recovery steps.
  • QA Officer: Reviews transformation efficiency and compliance documentation.

See also  Biosimilars: SOP for ELISA-Based Screening of Clones - V 2.0

4. Accountability

The Head of Biosimilars R&D is accountable for ensuring that transformation protocols are conducted according to validated procedures and that resulting data is accurately recorded.

5. Procedure

5.1 Materials Required

  • Chemically competent or electrocompetent E. coli cells
  • Plasmid DNA (purified)
  • SOC medium
  • Agar plates with appropriate antibiotic
  • Electroporator (for electroporation method)

5.2 Chemical Transformation Procedure

  1. Thaw 100 µL of chemically competent cells on ice.
  2. Add 1–5 ng of plasmid DNA gently and mix by tapping.
  3. Incubate the mixture on ice for 30 minutes.
  4. Heat shock at 42°C for 45 seconds.
  5. Immediately transfer tubes to ice for 2 minutes.
  6. Add 900 µL of SOC medium and incubate at 37°C for 1 hour with shaking (200 rpm).
  7. Plate 100–200 µL on LB agar containing the appropriate antibiotic.
  8. Incubate overnight at 37°C.

5.3 Electroporation Procedure

  1. Thaw 50 µL of electrocompetent cells on ice.
  2. Add 1–2 µL of plasmid DNA, mix gently.
  3. Transfer to pre-chilled 0.1 cm electroporation cuvette.
  4. Electroporate at 1.8 kV, 25 µF, 200 ohms (or follow equipment-specific settings).
  5. Immediately add 950 µL of SOC medium and transfer to sterile tube.
  6. Recover at 37°C for 1 hour, shaking at 200 rpm.
  7. Plate appropriate volumes on selective agar and incubate overnight.
See also  Biosimilars: SOP for Limiting Dilution Cloning - V 2.0

5.4 Post-Transformation Analysis

  1. Count colonies and record transformation efficiency using formula:

    Efficiency (cfu/µg DNA) = (colonies × dilution factor) / amount of DNA (µg)
  2. Log entries in Transformation Logbook (Annexure-1).

5.5 Storage and Record Keeping

  1. Inoculate confirmed transformants into LB broth and prepare glycerol stocks for long-term storage.
  2. Update transformation records and vector maps.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • SOC: Super Optimal Broth with Catabolite Repression
  • cfu: Colony Forming Units

7. Documents

  1. Transformation Logbook (Annexure-1)
  2. Glycerol Stock Record (Annexure-2)

8. References

  • ICH Q5D: Cell Substrate Derivation and Characterization
  • WHO TRS 978 – Annex on Recombinant DNA Technology
  • CDSCO R&D Laboratory Guidelines
See also  Biosimilars: SOP for Selection of Host Cell Lines - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Transformation Logbook

Date Strain Plasmid Method Colonies Efficiency Remarks
02/05/2025 DH5α pUC19 Chemical 850 4.2 × 106 Accepted

Annexure-2: Glycerol Stock Record

Date Clone ID Plasmid Volume Storage Temp Prepared By
03/05/2025 CL-DH5α-pUC19 pUC19 1 mL -80°C Rajesh Kumar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated transformation efficiency logging and included electroporation steps Annual revision
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Tablets: SOP for Monitoring Humidity During Tablet Packing – V 2.0
Next Post: Aerosol: SOP for Monitoring and Documenting Validation Batches – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version